Pyrazinone N-oxide nucleosides and analogs thereof
申请人:Research Foundation of State of N.Y.
公开号:US05192764A1
公开(公告)日:1993-03-09
This invention relates to nucleoside and acyclo analogs containing 5- or 6-substituted 2-pyrazinone-4-N-oxide. These compounds are useful for treating various conditions including viral infections, cancer, fungal infections, bacterial infections, microbial infections and related disease states. This invention also relates to pharmaceutical formulations containing these compounds. In addition, this invention relates to methods of treating the above-described conditions in animals and in particular, humans.
[EN] HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS<br/>[FR] COMPOSÉS ANTI-HYPERCHOLESTÉROLÉMIQUE À SUBSTITUTION HÉTÉROCYCLYLE
申请人:MERCK & CO INC
公开号:WO2008057336A2
公开(公告)日:2008-05-15
[EN] This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events. [FR] L'invention concerne des inhibiteurs de l'absorption du cholestérol de formule I : et ses sels pharmaceutiquement acceptables, R12 représentant un groupement alkyle hydroxylé et R9 contenant un cycle hétérocyclique. Les composés sont utiles pour l'abaissement des niveaux de cholestérol, notamment de cholestérol LDL, et pour le traitement de l'athérosclérose et la prévention des évènements athérosclérotiques.
[EN] TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS D'ACIDE AZACYCLOHEXYLE ACÉTIQUE SUBSTITUÉS PAR TRIAZOLE-PYRIDINYLE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR LPA
申请人:VIVA STAR BIOSCIENCES LTD
公开号:WO2022034568A1
公开(公告)日:2022-02-17
This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).